Trading Report: The Epizyme Inc. (EPZM) Receives “Outperform” Rating from Leerink Swann

The Epizyme Inc. (EPZM) Receives “Outperform” Rating from Leerink Swann

Epizyme Inc. (NASDAQ:EPZM)‘s stock had its “outperform” rating reiterated by stock analysts at Leerink Swann in a research report issued to clients and investors on Friday.

A number of other research firms have also recently issued reports on EPZM. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Mizuho reiterated a “buy” rating and issued a $18.00 target price on shares of Epizyme in a research report on Monday, June 20th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $26.00 target price on shares of Epizyme in a research report on Monday, June 20th. JMP Securities reiterated a “buy” rating and issued a $28.00 target price on shares of Epizyme in a research report on Thursday, June 23rd. Finally, HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Epizyme currently has an average rating of “Buy” and an average target price of $23.11.

Shares of Epizyme (NASDAQ:EPZM) traded down 1.37% during midday trading on Friday, hitting $9.39. 119,577 shares of the stock traded hands. The company’s market capitalization is $544.21 million. Epizyme has a 1-year low of $7.02 and a 1-year high of $18.29. The stock has a 50 day moving average of $8.70 and a 200 day moving average of $10.14.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.03. Epizyme had a negative return on equity of 43.05% and a negative net margin of 5,174.49%. Equities research analysts predict that Epizyme will post ($2.20) earnings per share for the current fiscal year.

In related news, insider Robert A. Copeland sold 4,000 shares of Epizyme stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $10.37, for a total value of $41,480.00. Following the transaction, the insider now directly owns 35,538 shares of the company’s stock, valued at $368,529.06. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 25.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. HBK Investments L P bought a new position in Epizyme during the first quarter worth approximately $149,000. SECOR Capital Advisors LP bought a new position in Epizyme during the second quarter worth approximately $620,000. JPMorgan Chase & Co. raised its position in Epizyme by 550.8% in the first quarter. JPMorgan Chase & Co. now owns 153,656 shares of the biopharmaceutical company’s stock worth $1,862,000 after buying an additional 130,044 shares in the last quarter. Renaissance Technologies LLC bought a new position in Epizyme during the first quarter worth approximately $356,000. Finally, Bank of New York Mellon Corp raised its position in Epizyme by 1.7% in the second quarter. Bank of New York Mellon Corp now owns 169,352 shares of the biopharmaceutical company’s stock worth $1,735,000 after buying an additional 2,866 shares in the last quarter. 80.79% of the stock is currently owned by institutional investors.

About Epizyme

Related posts

Leave a Comment